Abstract
Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Current Vascular Pharmacology
Title:Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Volume: 16 Issue: 1
Author(s): Vassiliki Mamakou, Ioanna Eleftheriadou, Niki Katsiki, Konstantinos Makrilakis, Konstantinos Tsioufis and Nikolaos Tentolouris*
Affiliation:
- First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens,Greece
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Abstract: Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Export Options
About this article
Cite this article as:
Mamakou Vassiliki , Eleftheriadou Ioanna , Katsiki Niki , Makrilakis Konstantinos , Tsioufis Konstantinos and Tentolouris Nikolaos*, Antidiabetic Drugs as Antihypertensives: New Data on the Horizon, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666171010122332
DOI https://dx.doi.org/10.2174/1570161115666171010122332 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Design of a Genetically Modified Soybean Protein Preventing Hypertension Based on an Anti-Hypertensive Peptide Derived from Ovalbumin
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Ion Channel Architecture of the Renal Microcirculation
Current Hypertension Reviews Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Current Vascular Pharmacology Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Preeclampsia: A Couples Disease with Maternal and Fetal Manifestations
Current Pharmaceutical Design Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry Correlation Between Circulating Adhesion Molecules and Resistin Levels in Hypertensive Type-2 Diabetic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Subject Index to Volume 1
Current Pharmacogenomics Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture
Current Drug Safety